Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 7Recruiting 3Unknown 1Not yet recruiting 1Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 72Breast Neoplasms 52Colorectal Neoplasms 46Neoplasms 37Multiple Myeloma 33Advanced Solid Tumors 32Recurrence 29Prostatic Neoplasms 29Pancreatic Neoplasms 27Ovarian Neoplasms 26Lung Neoplasms 26Carcinoma, Hepatocellular 26Neoplasm Metastasis 24Advanced Solid Tumor 20Small Cell Lung Carcinoma 19Leukemia, Myeloid, Acute 19Melanoma 17Endometrial Neoplasms 17Triple Negative Breast Neoplasms 14Stomach Neoplasms 14Lymphoma, Follicular 14Lymphoma 13Glioma 13Glioblastoma 13Lymphoma, B-Cell 12Squamous Cell Carcinoma of Head and Neck 11Uterine Cervical Neoplasms 10Head and Neck Neoplasms 10Leukemia 9Esophageal Neoplasms 9

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × INDUSTRY × Pathologic Processes × Clear all
NCT07162883 2025-09-09

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

Qilu Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
122 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Lymphatic Metastasis, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡